Coherus BioSciences, Inc. (NASDAQ:CHRS) provider of late-stage clinical biologics platform, is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.41 per share.
Looking ahead, the full year income are expected at $ 1.92 per share on the revenues of $ 494.57 million.
Previous Quarter Performance
Coherus BioSciences, Inc. came out with income for the second quarter of $ 0.81 per share, from the revenue of $ 135.67 million. According to street consensus, CHRS was expected to report 2Q20 income of $ 0.33 per share from revenue of $ 104.95 million. The bottom line results beat street analysts by $ 0.48 or 145.45 percent, at the same time, top line results outshined analysts by $ 30.72 million or 29.27 percent.
Stock Performance
Shares of Coherus BioSciences, Inc. traded up $ 0.97 or 5.68 percent on Wednesday, reaching $ 18.05 with volume of 1.04 million shares. Coherus BioSciences, Inc. has traded high as $ 18.46 and has cracked $ 17.07 on the downward trend
The closing price of $ 18.05, representing a 57.27 % increase from the 52 week low of $ 10.86 and a 25.84 % decrease over the 52 week high of $ 23.03.
The company has a market capital of $ 1.29 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Coherus BioSciences, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.coherus.com
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the bodys ability to fight infections. The company sells UDENYCA in the United States.
